Raltegravir thorough QT/QTc study: A single supratherapeutic dose of raltegravir does not prolong the QTcF interval

Journal of Clinical Pharmacology

Volumn 48, Issue 6, 2008, Pages 726-733

  Iwamoto, M ^a   Kost, J T ^a   Mistry, G C ^a   Wenning, L A ^a   Breidinger, S A ^a   Marbury, T C ^b   Stone, J A ^a   Gottesdiener, K M ^a   Bloomfield, D M ^a   Wagner, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

ECG; HIV 1 integrase inhibitor; QTc interval; Raltegravir; Thorough QT

Indexed keywords

INTEGRASE INHIBITOR; MOXIFLOXACIN; PLACEBO; RALTEGRAVIR;

AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART REPOLARIZATION; HUMAN; MALE; NAUSEA; NORMAL HUMAN; QT INTERVAL; QT PROLONGATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUPRATHERAPEUTIC DOSE; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; QUINOLINES; TIME FACTORS;

EID: 44049105253     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008318007     Document Type: Article

References (25)

1. Unaids. 2006 Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/en/Publications/default.asp. Accessed March 2, 2007.
2. Esposito D., Craigie R. HIV integrase structure and function. Adv Virus Res. 1999 ; 52: 319-333.
3. Asante-Appiah E., Skalka AM HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res. 1999 ; 52: 351-369.
4. Isentress [package insert]. Whitehouse Station, NJ: Merck & Co, Inc ; 2007.
5. Miller MD, Witmer M., Stillmock K., et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract THAA0302]. Presented at: XVI International AIDS Conference; August 13-18, 2006 ; Toronto, Canada ( International AIDS Society, Geneva, Switzerland, 2006 ).
6. Summa V., Pace P., Petrocchi A., et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials [abstract THPE0020]. Presented at: XVI International AIDS Conference; August 13-18, 2006 ; Toronto, Canada ( International AIDS Society, Geneva, Switzerland, 2006 ).
7. Markowitz M., Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 ; 43: 509-515.
8. Iwamoto M., Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008 ; 83: 293-299.
9. Grinsztejn B., Nguyen B. -Y, Katlama C., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007 ; 369: 1261-1269.
10. Cooper D., Gatell JM, Rockstroh J., et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105a LB]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections ; February 25-28, 2007 ; Los Angeles, California.
11. Steigbigel R., Kumar P., Eron J., et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract 105b LB]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections ; February 25-28, 2007 ; Los Angeles, California.
12. Markowitz M., Nguyen B-Y., Gotuzzo E. et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 ; 46: 125-133.
13. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005 ; 365: 682-686.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals: S7B. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005. Available at: http://www.ich.org/LOB/media/MEDIA2192.pdf.
15. Chaves AA, Zingaro GJ, Yordy MA, et al. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods. 2007 ; 56: 103-114.
16. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs: E14. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005. Available at: http://www.ich.org/LOB/media/MEDIA1476.pdf.
17. Malhotra BK, Glue P., Sweeney K., Anziano R., Mancuso J., Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007 ; 81: 377-385.
18. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M2 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005 ; 45: 1038-1047.
19. Extramiana F., Maison-Blanche P., Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther. 2005 ; 77: 247-258.
20. Noel GJ, Goodman DB, Chien S., Solanki B., Padmanabhan M., Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004 ; 44: 464-473.
21. Zhang L., Chappell J., Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007 ; 49: 146-153.
22. Merschman SA, Vallano PT, Wenning LA, et al. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 857: 15-19.
23. Kassahun K., McIntosh I., Cui D., et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos. 2007 ; 35: 1657-1663.
24. Mistry G., Wenning LA, Merschman S., et al. Atazanavir and ritonavir increase plasma levels of MK-0518 [abstract P291]. Presented at: 8th International Congress on Drug Therapy in HIV Infection ; November 12-16, 2006 ; Glasgow, Scotland.
25. Mistry G., Wenning LA, Petry A., et al. Atazanavir modestly increases plasma levels of MK-0518 [abstract MOPEB109]. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention ; July 22-25, 2007 ; Sydney, Australia.